Search

Your search keyword '"F. Ringeisen"' showing total 58 results

Search Constraints

Start Over You searched for: Author "F. Ringeisen" Remove constraint Author: "F. Ringeisen"
58 results on '"F. Ringeisen"'

Search Results

2. Interaction of GeH 4 with the Ge(100)2 × 1 surface

3. Growth of a Ge/Si/Ge (100) heterostructure by very low pressure chemical vapour deposition using Si2H6 and GeH4 gases—photoemission and low energy electron diffraction studies

4. Thermal and catalytic decomposition of Si2H6 on a Ge(100)2 × 1 surface: Photoemission and LEED studies

5. Condensation of disilane or germane on a metallic surface: a photoemission study

6. Interfacial reaction between disilane and a Ge(111)c(2 × 8) surface

8. Monohydride phase on Ge(111) and amorphous germanium surfaces: a photoemission study

9. Adsorption de disilane sur Si(111) 7 × 7. Influence de l'hydrogène

10. Photoemission study of low pressure hydrogen and disilane adsorption on Si(111) 7 × 7 and Ge(111)

11. Using decomposed disilane as a gas source for Si epitaxial growth on Ge (111): Photoemission studies

12. Room temperature disilane adsorption on Si(111) and Ge(111) studied by UPS: a comparative study

13. Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome

14. Photoemission study of the thermal and catalytic decomposition of germane on a Si(111)7 x 7 surface

16. Comparative photoemission study of low-pressure hydrogen, silane, and disilane adsorption on Si(111)7 x 7

17. Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: Final results of a phase II study

19. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC)

20. Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma

21. Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC)

24. A photoemission investigation of the Si-Au interface and its behaviour under oxygen exposure

25. Interfacial reaction between monosilane and a polycrystalline tantalum substrate

26. Photoemission study of low pressure silane adsorption on Si(111)7 × 7

27. XPS, ESR and resistivity measurements on amorphous silicon oxynitride films (a-SiOxNy) prepared by reactive evaporation of Si in presence of NO2

28. Hydrogenation of amorphized silicon by low energy H+ ion bombardment studied by UPS

29. STRUCTURE AND GROWTH KINETICS OF SiO2 ULTRA THIN FILM ON Si(111) SURFACE

30. Broken-dimer model in a-Si:H

31. HYDROGENATION OF AMORPHIZED SILICON STUDIED BY UPS

32. REVERSIBLE PROCESS OF HYDROGEN ADSORPTION ON SI(111)

33. Band bending variation of the Si(111) surface during its thermal oxidation

35. Formation and properties of the copper silicon(111) interface

36. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.

37. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.

38. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.

39. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.

40. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2 - advanced breast cancer: results from BOLERO-2.

41. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

42. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.

43. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

44. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

45. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.

46. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

47. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer.

48. [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].

49. [Breast carcinoma with predominant neuroendocrine differentiation].

50. Functional analysis of ground squirrel hepatitis virus enhancer II.

Catalog

Books, media, physical & digital resources